UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/606,879	06/27/2003	Lieven Stuyver	BJS-2551-123	5237
	7590 12/18/200 NDERHYE, PC	EXAMINER		
901 NORTH GLEBE ROAD, 11TH FLOOR ARLINGTON, VA 22203			PENG, BO	
ARLINGTON, VA 22203			ART UNIT	PAPER NUMBER
			1648	
			MAIL DATE	DELIVERY MODE
			12/18/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/606,879	STUYVER ET AL.	
Examiner	Art Unit	
BO PENG	1648	

		BOTENO	1040	
	The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence address	
THE	REPLY FILED 08 December 2009 FAILS TO PLACE THIS	S APPLICATION IN CONDITION	FOR ALLOWANCE.	
1. 🛚	The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appetor Continued Examination (RCE) in compliance with 37 Coperiods:	replies: (1) an amendment, affida eal (with appeal fee) in compliance	vit, or other evidence, which places the e with 37 CFR 41.31; or (3) a Request	
a)	The period for reply expiresmonths from the mailing	g date of the final rejection.		
b)	The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire a Examiner Note: If box 1 is checked, check either box (a) or (ater than SIX MONTHS from the maili (b). ONLY CHECK BOX (b) WHEN TH	ng date of the final rejection.	
have under set fo may r	MONTHS OF THE FINAL REJECTION. See MPEP 706.07(sions of time may be obtained under 37 CFR 1.136(a). The date been filed is the date for purposes of determining the period of exists 37 CFR 1.17(a) is calculated from: (1) the expiration date of the sorth in (b) above, if checked. Any reply received by the Office later educe any earned patent term adjustment. See 37 CFR 1.704(b). ICE OF APPEAL	on which the petition under 37 CFR 1. tension and the corresponding amoun shortened statutory period for reply original three months after the mailing days.	t of the fee. The appropriate extension fee ginally set in the final Office action; or (2) as	
	The Notice of Appeal was filed on <u>08 December 2009</u> . A the date of filing the Notice of Appeal (37 CFR 41.37(a)), appeal. Since a Notice of Appeal has been filed, any reply NDMENTS	or any extension thereof (37 CFR	41.37(e)), to avoid dismissal of the	Ŧ
	The proposed amendment(s) filed after a final rejection, to the proposed amendment(s) filed after a final rejection, to the proposed amendment(s) They raise the issue of new matter (see NOTE below).	nsideration and/or search (see NC w);	DTE below);	
	 (c) They are not deemed to place the application in bet appeal; and/or (d) They present additional claims without canceling a NOTE: See Continuation Sheet. (See 37 CFR 1.1 	corresponding number of finally re 16 and 41.33(a)).	jected claims.	
4. 🖳	•		ompliant Amendment (PTOL-324).	
5. 上				
6. ∟ - □	non-allowable claim(s).			
7. 🔀	how the new or amended claims would be rejected is provided that the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: 35,36 and 38. Claim(s) rejected: 16,28,29 and 35-40.	vided below or appended.	vill be entered and an explanation of	
ΔFFI	Claim(s) withdrawn from consideration: <u>18-27,31,32 and 3</u> DAVIT OR OTHER EVIDENCE	<u>34</u> .		
8. 🗌	The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).	d sufficient reasons why the affida	vit or other evidence is necessary and	
	The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	overcome <u>all</u> rejections under apper y and was not earlier presented. S	eal and/or appellant fails to provide a See 37 CFR 41.33(d)(1).	
	The affidavit or other evidence is entered. An explanation UEST FOR RECONSIDERATION/OTHER	n of the status of the claims after	entry is below or attached.	
11. 🏻	The request for reconsideration has been considered bu See Continuation Sheet.	t does NOT place the application	in condition for allowance because:	
	Note the attached Information <i>Disclosure Statement</i> (s). (Other:	(PTO/SB/08) Paper No(s)		
		/BO PENG/		
		Primary Examiner, Art	Unit 1648	

Continuation of 3. NOTE: New limitations added to the claims 36 step (iv) raise new issue and require new search and further consideration.

Continuation of 11. does NOT place the application in condition for allowance because: Applicants' arguments are not sufficient to overcome all outstranding rejections:

In response to the rejection of Claims 16, 28, 29 and 35-40 under 35 U.S.C. 112, 1st, Applicants argue that the claims are supported by an adequate written description and that one of ordinary skill will be able to make and use the claimed invention without undue experimentation. This argument is not sufficient to overcome the rejection. As indicated in the Final Office action, para 13, the scope of new Claim 36 encompasses use of any undefined nucleotide probes of about 5 to 50 nucleotides long to specifically detect "the presence or absence of HBV genotype A", but not other HBV genotypes, in a sample. However, the newly cited primers SEQ ID NOs: 75, 76, 94, 105, 112, 134 and 135 appear to overlap with HBV genomes of other genotypes see Specification, Fig. 1., indicating that the cited primers are not genotype-specific. Since the cited primers in Claim 36 cannot yield the required result of" determining the presence or absence of HBV genotype A in a biological sample" cited in the preamble of Claim 36, one of ordinary skill in the art will NOT be able to make and use the claimed invention, without undue experimentation.

In response to the 103 rejection of Claims 36 and 39, Applicants argue that the four primers as indicated amplify the HBsAg region of many different genotypes in a very efficient way, and the use of these primers is an unexpected advantage of the claimed invention. This argument is considered, but not persuasive. This argument is not relevant to the claims. It is noted that "the four primers" are not required in the claimed method. See Para 19, the final office action, dated June 8, 2009.

If the amendment were entered, the objection to Claim 38 under 37 CFR 1.75, as being a substantial duplicate of claim 29, would be moot in view of the amendment to the claim. The objection to Claims 35 and 36 as indefinite would be withdrawn in view of the amendment to the claims.

If the amendment were entered, the rejection of Claims 16 and 35 under 35 U.S.C. 112, 1st would be withdrawn.